Literature DB >> 12219774

Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections.

George Z Rassidakis1, Dan Jones, Athanasios Thomaides, Filiz Sen, Raymond Lai, Fernando Cabanillas, Timothy J McDonnell, L Jeffrey Medeiros.   

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas with a wide spectrum of clinicopathologic features, and apoptosis mechanisms may have a role in lymphomagenesis. We assessed apoptotic rate (AR) in 112 PTCLs using a tissue microarray developed in our laboratory and a modified terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. The mean AR was 1.47% +/- 1.38% for the entire group of PTCLs (range, 0.06%-5.15%), and AR varied significantly among different tumor types. In mycosis fungoides, the mean AR was 0.74%; angioimmunoblastic T-cell lymphoma, 1.02%; PTCL, not otherwise specified, 1.38%; cutaneous anaplastic large cell lymphoma (ALCL), 1.41%; anaplastic lymphoma kinase protein (ALK)-negative ALCL, 1.43%; extranodal natural killer/T-cell lymphoma of nasal type, 2.04%; ALK-positive ALCL, 2.95%; and enteropathy-type T-cell lymphoma, 3.06%. Mean AR was higher in PTCL with large cell vs small/medium cell morphologic features (1.66% +/- 1.1% vs 0.99% +/- 1.0%). In a subset of 33 PTCLs, the tissue microarray results comparedfavorably with those obtained in full tissue sections. We conclude that the highest ARs in PTCLs are found in enteropathy-type T-cell lymphoma and ALK-positive ALCL, and that AR can be assessed reliably by using a tissue microarray.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12219774     DOI: 10.1309/HKMV-VMPP-0CH8-3DPQ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

1.  Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics.

Authors:  Wenjin Chen; David J Foran
Journal:  Anal Chim Acta       Date:  2006-01-23       Impact factor: 6.558

2.  Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Francisco Vega; L Jeffrey Medeiros; Vasiliki Leventaki; Coralyn Atwell; Jeong Hee Cho-Vega; Ling Tian; Francois-Xavier Claret; George Z Rassidakis
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

3.  JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis.

Authors:  George Z Rassidakis; Athanasios Thomaides; Coralyn Atwell; Richard Ford; Dan Jones; Francois-Xavier Claret; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2005-10       Impact factor: 7.842

4.  Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma.

Authors:  George Z Rassidakis; Marianna Feretzaki; Coralyn Atwell; Ioannis Grammatikakis; Quan Lin; Raymond Lai; Francois-Xavier Claret; L Jeffrey Medeiros; Hesham M Amin
Journal:  Blood       Date:  2004-09-16       Impact factor: 22.113

5.  Retinoblastoma protein is frequently absent or phosphorylated in anaplastic large-cell lymphoma.

Authors:  George Z Rassidakis; Raymond Lai; Marco Herling; Candy Cromwell; Annette Schmitt-Graeff; L Jeffrey Medeiros
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

6.  Fluorescent probes detecting the phagocytic phase of apoptosis: enzyme-substrate complexes of topoisomerase and DNA.

Authors:  Candace L Minchew; Vladimir V Didenko
Journal:  Molecules       Date:  2011-06-03       Impact factor: 4.411

7.  Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs.

Authors:  Joel D Pearson; Jingxi Zhang; Zuoqiao Wu; Kayla D Thew; Katelynn J Rowe; Julinor T C Bacani; Robert J Ingham
Journal:  Mol Cancer       Date:  2014-08-29       Impact factor: 27.401

Review 8.  Tissue microarrays for high-throughput molecular pathology.

Authors:  Khawla Al Kuraya; Ronald Simon; Guido Sauter
Journal:  Ann Saudi Med       Date:  2004 May-Jun       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.